8-K filed Mar 4, 2026 at 16:03 ET
{ "summary": "Keros Therapeutics reported a full-year net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, primarily due to $205.4 million in license revenue from Takeda. The company also announced leadership changes and upcoming clinical trial milestones for rinvatercept in DMD and ALS. Cash reserves declined to $287.4 million from $559.9 million, largely due to a share repurchase and tender offer.", "sentiment": "mixed", "impactScore": 6